References

Abdullah, H. M., Ullah, W., Jafar, M. S., van Zyl, M., Saeed, R., Alam, M., Alraies, M. C., & Fischman, D. L. (2021). Safety and efficacy of apixaban, rivaroxaban, and warfarin in end-stage renal disease with atrial fibrillation: a systematic review and meta-analysis. Cardiovascular Revascularization Medicine, 30, 26-32.

Ageno, W., Bertù, L., Bucherini, E., Camporese, G., Dentali, F., Iotti, M., Lessiani, G., Parisi, R., Prandoni, P., & Sartori, M. (2022). Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. bmj, 379.

Ageno, W., Beyer Westendorf, J., Contino, L., Bucherini, E., Sartori, M. T., Senzolo, M., Grandone, E., Santoro, R., Carrier, M., & Delluc, A. (2022). Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. Blood advances, 6(12), 3569-3578.

Ageno, W., Vedovati, M. C., Cohen, A., Huisman, M., Bauersachs, R., Gussoni, G., Becattini, C., & Agnelli, G. (2021). Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and haemostasis, 121(05), 616-624.

Ageno, W., Vedovati, M. C., Cohen, A., Huisman, M., Bauersachs, R., Gussoni, G., Becattini, C., & Agnelli, G. (2021). Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thromb Haemost, 121(5), 616-624. https://doi.org/10.1055/s-0040-1720975

Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M. V., Connors, J. M., Cohen, A., Bauersachs, R., Brenner, B., & Torbicki, A. (2020). Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine, 382(17), 1599-1607.

Agnelli, G., Muñoz, A., Franco, L., Mahé, I., Brenner, B., Connors, J. M., Gussoni, G., Hamulyak, E. N., Lambert, C., & Suero, M. R. (2022). Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and haemostasis, 122(05), 796-807.

Al Sulaiman, K., Badreldin, H. A., Korayem, G. B., Alenazi, A. A., Alsuwayyid, F., Alrashidi, A., Alhijris, M., Almutairi, F., Alharthi, F., & Vishwakarma, R. (2022). Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study. Thrombosis Journal, 20(1), 25.

Alberts, M., Chen, Y.-W., Lin, J. H., Kogan, E., Twyman, K., & Milentijevic, D. (2020). Risks of stroke and mortality in atrial fibrillation patients treated with rivaroxaban and warfarin. Stroke, 51(2), 549-555.

Ansell, J., Bakhru, S., Laulicht, B. E., Tracey, G., Villano, S., & Freedman, D. (2022). Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects. European heart journal, 43(10), 985-992.

Ashton, V., Kerolus-Georgi, S., & Moore, K. T. (2021). The pharmacology, efficacy, and safety of rivaroxaban in renally impaired patient populations. The Journal of Clinical Pharmacology, 61(8), 1010-1026.

Ashton, V., Mudarris, L., & Moore, K. T. (2021). The pharmacology, efficacy, and safety of rivaroxaban in obese patient populations. American Journal of Cardiovascular Drugs, 21(3), 283-297.

Aslan, O., & Yildirim, S. (2022). Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data. Turkish Journal of Medical Sciences, 52(4), 948-957.

Attelind, S., Hallberg, P., Wadelius, M., Hamberg, A.-K., Siegbahn, A., Granger, C. B., Lopes, R. D., Alexander, J. H., Wallentin, L., & Eriksson, N. (2022). Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events. Frontiers in Genetics, 13, 982955.

Bainey, K. R., Welsh, R. C., Connolly, S. J., Marsden, T., Bosch, J., Fox, K. A., Steg, P. G., Vinereanu, D., Connolly, D. L., & Berkowitz, S. D. (2020). Rivaroxaban plus aspirin versus aspirin alone in patients with prior percutaneous coronary intervention (COMPASS-PCI). Circulation, 141(14), 1141-1151.

Bonaca, M. P., Bauersachs, R. M., Anand, S. S., Debus, E. S., Nehler, M. R., Patel, M. R., Fanelli, F., Capell, W. H., Diao, L., & Jaeger, N. (2020). Rivaroxaban in peripheral artery disease after revascularization. New England Journal of Medicine, 382(21), 1994-2004.

Bonde, A. N., Martinussen, T., Lee, C. J.-Y., Lip, G. Y., Staerk, L., Bang, C. N., Bhattacharya, J., Gislason, G., Torp-Pedersen, C., & Olesen, J. B. (2020). Rivaroxaban versus apixaban for stroke prevention in atrial fibrillation: an instrumental variable analysis of a nationwide cohort. Circulation: Cardiovascular Quality and Outcomes, 13(4), e006058.

Chen, C., Cao, Y., Zheng, Y., Dong, Y., Ma, J., Zhu, W., & Liu, C. (2021). Effect of rivaroxaban or apixaban in atrial fibrillation patients with stage 4–5 chronic kidney disease or on dialysis. Cardiovascular Drugs and Therapy, 35, 273-281.

Chiv, R., Beradid, S., Suissa, S., & Renoux, C. (2024). Effectiveness and Safety of Edoxaban Compared With Apixaban in Elderly Patients With Nonvalvular Atrial Fibrillation: A Real-World Population-Based Cohort Study. Stroke.

Cohen, A. T., Pan, S., Byon, W., Ilyas, B. S., Taylor, T., & Lee, T. C. (2021). Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy, 38, 3003-3018.

Connolly, S. J., Karthikeyan, G., Ntsekhe, M., Haileamlak, A., El Sayed, A., El Ghamrawy, A., Damasceno, A., Avezum, A., Dans, A. M., & Gitura, B. (2022). Rivaroxaban in rheumatic heart disease–associated atrial fibrillation. New England Journal of Medicine, 387(11), 978-988.

Connor, P., Sánchez van Kammen, M., Lensing, A. W., Chalmers, E., Kállay, K., Hege, K., Simioni, P., Biss, T., Bajolle, F., & Bonnet, D. (2020). Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood advances, 4(24), 6250-6258.

Costa, O. S., Beyer-Westendorf, J., Ashton, V., Milentijevic, D., Moore, K. T., Bunz, T. J., & Coleman, C. I. (2020). Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. Current Medical Research and Opinion, 36(7), 1081-1088.

Dawwas, G. K., Leonard, C. E., Lewis, J. D., & Cuker, A. (2022). Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data. Annals of internal medicine, 175(1), 20-28.

de Vries, T. A., Hirsh, J., Xu, K., Mallick, I., Bhagirath, V. C., Eikelboom, J. W., Ginsberg, J. S., Kruger, P. C., & Chan, N. C. (2020). Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?—a systematic review. Thrombosis and haemostasis, 120(09), 1323-1329.

De Vriese, A. S., Caluwé, R., Van Der Meersch, H., De Boeck, K., & De Bacquer, D. (2021). Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. Journal of the American Society of Nephrology, 32(6), 1474-1483.

Ercisli, M. F., Lechun, G., Azeez, S. H., Hamasalih, R. M., Song, S., & Aziziaram, Z. (2021). Relevance of genetic polymorphisms of the human cytochrome P450 3A4 in rivaroxaban-treated patients. Cellular, Molecular and Biomedical Reports, 1(1), 33-41.

Escobar-Cervantes, C., Díez-Villanueva, P., Bonanad Lozano, C., Reino, A. P., Almendro-Delia, M., Facila, L., Valle, A., & Suárez, C. (2023). Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation. Expert review of cardiovascular therapy, 21(11), 791-802.

Esmaeili, S., Abolmaali, M., Aarabi, S., Motamed, M. R., Chaibakhsh, S., Joghataei, M. T., Mojtahed, M., & Mirzaasgari, Z. (2021). Rivaroxaban for the treatment of cerebral venous thrombosis. BMC neurology, 21, 1-6.

Fernandez, S., Lenoir, C., Samer, C. F., & Rollason, V. (2021). Drug-drug interactions leading to adverse drug reactions with rivaroxaban: A systematic review of the literature and analysis of VigiBase. Journal of Personalized Medicine, 11(4), 250.

Fernandez, S., Lenoir, C., Samer, C., & Rollason, V. (2020). Drug interactions with apixaban: a systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports. Pharmacology research & perspectives, 8(5), e00647.

Fralick, M., Colacci, M., Schneeweiss, S., Huybrechts, K. F., Lin, K. J., & Gagne, J. J. (2020). Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Annals of internal medicine, 172(7), 463-473.

Fu, E. L., Desai, R. J., Paik, J. M., Kim, D. H., Zhang, Y., Mastrorilli, J. M., Cervone, A., & Lin, K. J. (2024). Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: nationwide US cohort study. American Journal of Kidney Diseases, 83(3), 293-305. e291.

Geisler, T., Keller, T., Martus, P., Poli, K., Serna-Higuita, L. M., Schreieck, J., Gawaz, M., Tünnerhoff, J., Bombach, P., & Nägele, T. (2023). Apixaban versus aspirin for embolic stroke of undetermined source. NEJM evidence, 3(1), EVIDoa2300235.

Grymonprez, M., De Backer, T. L., Bertels, X., Steurbaut, S., & Lahousse, L. (2023). Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study. Frontiers in pharmacology, 14, 1125576.

Guimaraes, H. P., e Silva, P. G. d. B., Liporace, I. L., Sampaio, R. O., Tarasoutchi, F., Paixão, M., Hoffmann-Filho, C. R., Patriota, R., Leiria, T. L., & Lamprea, D. (2021). A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: rationale and design of the RIVER trial. American heart journal, 231, 128-136.

Guimarães, H. P., Lopes, R. D., de Barros e Silva, P. G., Liporace, I. L., Sampaio, R. O., Tarasoutchi, F., Hoffmann-Filho, C. R., de Lemos Soares Patriota, R., Leiria, T. L., & Lamprea, D. (2020). Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. New England Journal of Medicine, 383(22), 2117-2126.

Gulilat, M., Keller, D., Linton, B., Pananos, A. D., Lizotte, D., Dresser, G. K., Alfonsi, J., Tirona, R. G., Kim, R. B., & Schwarz, U. I. (2020). Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. Journal of Thrombosis and Thrombolysis, 49, 294-303.

Hanni, C., Petrovitch, E., Ali, M., Gibson, W., Giuliano, C., Holzhausen, J., Makowski, C., Pallisco, A., Patel, N., & Sutter, D. (2020). Outcomes associated with apixaban vs warfarin in patients with renal dysfunction. Blood Advances, 4(11), 2366-2371.

Hanon, O., Vidal, J.-S., Pisica-Donose, G., Orvoën, G., David, J.-P., Chaussade, E., Caillard, L., de Jong, L. W., Boulloche, N., & Vinsonneau, U. (2021). Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart, 107(17), 1376-1382.

Healey, J. S., Lopes, R. D., Granger, C. B., Alings, M., Rivard, L., McIntyre, W. F., Atar, D., Birnie, D. H., Boriani, G., & Camm, A. J. (2024). Apixaban for stroke prevention in subclinical atrial fibrillation. New England Journal of Medicine, 390(2), 107-117.

Hernandez, A. V., Bradley, G., Khan, M., Fratoni, A., Gasparini, A., Roman, Y. M., Bunz, T. J., Eriksson, D., Meinecke, A.-K., & Coleman, C. I. (2020). Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes. European Heart Journal-Quality of Care and Clinical Outcomes, 6(4), 301-307.

Hill, N. R., Sandler, B., Bergrath, E., Milenkovic, D., Ashaye, A. O., Farooqui, U., & Cohen, A. T. (2020). A systematic review of network meta-analyses and real-world evidence comparing apixaban and rivaroxaban in nonvalvular atrial fibrillation. Clinical and Applied Thrombosis/Hemostasis, 26, 1076029619898764.

Hua, Y., Sun, J.-Y., Su, Y., Qu, Q., Wang, H.-Y., Sun, W., & Kong, X.-Q. (2021). The safety and efficacy of rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a systematic review and meta-analysis. American Journal of Cardiovascular Drugs, 21, 51-61.

Jakowenko, N., Nguyen, S., Ruegger, M., Dinh, A., Salazar, E., & Donahue, K. R. (2020). Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system. Thrombosis research, 196, 276-282.

Jaksa, A., Gibbs, L., Kent, S., Rowark, S., Duffield, S., Sharma, M., Kincaid, L., Ali, A. K., Patrick, A. R., & Govil, P. (2022). Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study. BMJ open, 12(10), e064662.

Jamieson, M. J., Byon, W., Dettloff, R. W., Crawford, M., Gargalovic, P. S., Merali, S. J., Onorato, J., Quintero, A. J., & Russ, C. (2022). Apixaban use in obese patients: a review of the pharmacokinetic, interventional, and observational study data. American Journal of Cardiovascular Drugs, 22(6), 615-631.

Jansson, M., Själander, S., Sjögren, V., Renlund, H., Norrving, B., & Själander, A. (2020). Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation. Thrombosis Research, 185, 135-141.

Koehl, J. L., Hayes, B. D., Al-Samkari, H., & Rosovsky, R. (2020). A comprehensive evaluation of apixaban in the treatment of venous thromboembolism. Expert Review of Hematology, 13(2), 155-173.

Konicki, R., Weiner, D., Herbert Patterson, J., Gonzalez, D., Kashuba, A., Cao, Y. C., Gehi, A. K., Watkins, P., & Powell, J. R. (2020). Rivaroxaban precision dosing strategy for real-world atrial fibrillation patients. Clinical and Translational Science, 13(4), 777-784.

Labovitz, A. J., Rose, D. Z., Fradley, M. G., Meriwether, J. N., Renati, S., Martin, R., Kasprowicz, T., Murtagh, R., Kip, K., & Beckie, T. M. (2021). Early apixaban use following stroke in patients with atrial fibrillation: results of the AREST trial. Stroke, 52(4), 1164-1171.

Lau, W. C., Cheung, C.-L., Man, K. K., Chan, E. W., Sing, C. W., Lip, G. Y., Siu, C.-W., Lam, J. K., Lee, A. C., & Wong, I. C. (2020). Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and risk for osteoporotic fractures among patients with atrial fibrillation: a population-based cohort study. Annals of internal medicine, 173(1), 1-9.

Lau, W. C., Torre, C. O., Man, K. K., Stewart, H. M., Seager, S., Van Zandt, M., Reich, C., Li, J., Brewster, J., & Lip, G. Y. (2022). Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study. Annals of internal medicine, 175(11), 1515-1524.

Lin, S. Y., Kuo, C. H., Yeh, S. J., Tsai, L. K., Liu, Y. B., Huang, C. F., Tang, S. C., & Jeng, J. S. (2020). Real-world rivaroxaban and apixaban levels in asian patients with atrial fibrillation. Clinical Pharmacology & Therapeutics, 107(1), 278-286.

Mahe, I., Agnelli, G., Ay, C., Bamias, A., Becattini, C., Carrier, M., Chapelle, C., Cohen, A. T., Girard, P., & Huisman, M. V. (2022). Extended anticoagulant treatment with full-or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT study. Thrombosis and haemostasis, 122(04), 646-656.

Male, C., Lensing, A. W., Palumbo, J. S., Kumar, R., Nurmeev, I., Hege, K., Bonnet, D., Connor, P., Hooimeijer, H. L., & Torres, M. (2020). Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. The Lancet Haematology, 7(1), e18-e27.

Mamas, M. A., Batson, S., Pollock, K. G., Grundy, S., Matthew, A., Chapman, C., Manuel, J. A., Farooqui, U., & Mitchell, S. A. (2022). Meta-analysis comparing apixaban versus rivaroxaban for management of patients with nonvalvular atrial fibrillation. The American journal of cardiology, 166, 58-64.

Matoba, T., Yasuda, S., Kaikita, K., Akao, M., Ako, J., Nakamura, M., Miyauchi, K., Hagiwara, N., Kimura, K., & Hirayama, A. (2021). Rivaroxaban monotherapy in patients with atrial fibrillation after coronary stenting: insights from the AFIRE trial. Cardiovascular Interventions, 14(21), 2330-2340.

Mavrakanas, T. A., Garlo, K., & Charytan, D. M. (2020). Apixaban versus no anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation. Clinical Journal of the American Society of Nephrology, 15(8), 1146-1154.

Mavri, A., Vene, N., Božic-Mijovski, M., Miklic, M., Söderblom, L., Pohanka, A., Malmström, R. E., & Antovic, J. (2021). Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation. Scientific Reports, 11(1), 13908.

McBane II, R. D., Loprinzi, C. L., Zemla, T., Tafur, A., Sanfilippo, K., Liu, J. J., Garcia, D. A., Heun, J., Gundabolu, K., & Onitilo, A. A. (2024). Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial. Journal of Thrombosis and Haemostasis.

McBane II, R. D., Wysokinski, W. E., Le-Rademacher, J. G., Zemla, T., Ashrani, A., Tafur, A., Perepu, U., Anderson, D., Gundabolu, K., & Kuzma, C. (2020). Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. Journal of Thrombosis and Haemostasis, 18(2), 411-421.

Mentias, A., Heller, E., & Vaughan Sarrazin, M. (2020). Comparative effectiveness of rivaroxaban, apixaban, and warfarin in atrial fibrillation patients with polypharmacy. Stroke, 51(7), 2076-2086.

Miao, B., Sood, N., Bunz, T. J., & Coleman, C. I. (2020). Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis. European journal of haematology, 104(4), 328-335.

Mokadem, M. E., Hassan, A., & Algaby, A. Z. (2021). Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular, 29(5), 745-750.

O’Kane, C. P., Avalon, J. C. O., Lacoste, J. L., Fang, W., Bianco, C. M., Davisson, L., & Piechowski, K. L. (2022). Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI≥ 50 kg/m2. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 42(2), 112-118.

Perreault, S., Cote, R., Dragomir, A., White-Guay, B., Lenglet, A., & Dorais, M. (2022). Effectiveness and safety of low-dose versus standard-dose rivaroxaban and apixaban in patients with atrial fibrillation. Plos one, 17(12), e0277744.

Perreault, S., Dragomir, A., Cote, R., Lenglet, A., White-Guay, B., De Denus, S., Schnitzer, M. E., Dubé, M. P., Brophy, J. M., & Dorais, M. (2021). Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 41(4), 379-393.

Petzold, T., Thienel, M., Dannenberg, L., Mourikis, P., Helten, C., Ayhan, A., M’Pembele, R., Achilles, A., Trojovky, K., & Konsek, D. (2020). Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1. Circulation Research, 126(4), 486-500.

Piccini, J. P., Caso, V., Connolly, S. J., Fox, K. A., Oldgren, J., Jones, W. S., Gorog, D. A., Durdil, V., Viethen, T., & Neumann, C. (2022). Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. The lancet, 399(10333), 1383-1390.

Planquette, B., Bertoletti, L., Charles-Nelson, A., Laporte, S., Grange, C., Mahé, I., Pernod, G., Elias, A., Couturaud, F., & Falvo, N. (2022). Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest, 161(3), 781-790.

Pokorney, S. D., Chertow, G. M., Al-Khalidi, H. R., Gallup, D., Dignacco, P., Mussina, K., Bansal, N., Gadegbeku, C. A., Garcia, D. A., & Garonzik, S. (2022). Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation, 146(23), 1735-1745.

Ramacciotti, E., Agati, L. B., Calderaro, D., Aguiar, V. C. R., Spyropoulos, A. C., de Oliveira, C. C. C., Dos Santos, J. L., Volpiani, G. G., Sobreira, M. L., & Joviliano, E. E. (2022). Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. The lancet, 399(10319), 50-59.

Ray, W. A., Chung, C. P., Stein, C. M., Smalley, W., Zimmerman, E., Dupont, W. D., Hung, A. M., Daugherty, J. R., Dickson, A., & Murray, K. T. (2021). Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. Jama, 326(23), 2395-2404.

Rivera-Caravaca, J. M., Sanchez, M. A., Fernández, M. S., Rafols, C., Barón-Esquivias, G., Ynsaurriaga, F. A., Freixa-Pamias, R., Goya, I. L., Rodríguez, J. M. V., & Pérez-Cabeza, A. I. (2023). Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment. The American Journal of Cardiology, 203, 122-127.

Rutherford, O.-C. W., Jonasson, C., Ghanima, W., Söderdahl, F., & Halvorsen, S. (2020). Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. European Heart Journal-Cardiovascular Pharmacotherapy, 6(2), 75-85.

Samama, C. M., Laporte, S., Rosencher, N., Girard, P., Llau, J., Mouret, P., Fisher, W., Martínez-Martín, J., Duverger, D., & Deygas, B. (2020). Rivaroxaban or enoxaparin in nonmajor orthopedic surgery. New England Journal of Medicine, 382(20), 1916-1925.

Speed, V., Green, B., Roberts, L. N., Woolcombe, S., Bartoli-Abdou, J., Barsam, S., Byrne, R., Gee, E., Czuprynska, J., & Brown, A. (2020). Fixed dose rivaroxaban can be used in extremes of bodyweight: a population pharmacokinetic analysis. Journal of Thrombosis and Haemostasis, 18(9), 2296-2307.

Spyropoulos, A. C., Ageno, W., Albers, G. W., Elliott, C. G., Halperin, J. L., Hiatt, W. R., Maynard, G. A., Steg, P. G., Weitz, J. I., & Lu, W. (2020). Post-discharge prophylaxis with rivaroxaban reduces fatal and major thromboembolic events in medically ill patients. Journal of the American College of Cardiology, 75(25), 3140-3147.

Stanifer, J. W., Pokorney, S. D., Chertow, G. M., Hohnloser, S. H., Wojdyla, D. M., Garonzik, S., Byon, W., Hijazi, Z., Lopes, R. D., & Alexander, J. H. (2020). Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation, 141(17), 1384-1392.

Suzuki, S., Yamashita, T., Akao, M., Okumura, K., & investigators, J.-E. A. (2020). Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis. European Journal of Clinical Pharmacology, 76, 1111-1124.

Tittl, L., Marten, S., Naue, C., & Beyer-Westendorf, J. (2021). 5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry. Thrombosis Research, 202, 24-30.

Wang, T. Y., Svensson, L. G., Wen, J., Vekstein, A., Gerdisch, M., Rao, V. U., Moront, M., Johnston, D., Lopes, R. D., & Chavez, A. (2023). Apixaban or warfarin in patients with an On-X mechanical aortic valve. NEJM evidence, 2(7), EVIDoa2300067.

Weir, M. R., Ashton, V., Moore, K. T., Shrivastava, S., Peterson, E. D., & Ammann, E. M. (2020). Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. American heart journal, 223, 3-11.

Wetmore, J. B., Herzog, C. A., Yan, H., Reyes, J. L., Weinhandl, E. D., & Roetker, N. S. (2022). Apixaban versus warfarin for treatment of venous thromboembolism in patients receiving long-term dialysis. Clinical Journal of the American Society of Nephrology, 17(5), 693-702.

Whitehouse, K. R., Avula, D., Kahlon, T., Costelle, D., Dunbar-Matos, C., Pahwa, S., Trivedi, J. R., & Slaughter, M. S. (2022). Apixaban: Alternative anticoagulation for HeartMate 3 ventricular assist device. ASAIO Journal, 68(3), 318-322.

Woller, S. C., Stevens, S. M., Kaplan, D., Wang, T.-F., Branch, D. W., Groat, D., Wilson, E. L., Armbruster, B., Aston, V. T., & Lloyd, J. F. (2022). Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Advances, 6(6), 1661-1670.

Xu, Y., Chang, A. R., Inker, L. A., McAdams-DeMarco, M., Grams, M. E., & Shin, J.-I. (2023). Associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease. Circulation, 148(19), 1445-1454.

Yang, L., Brooks, M. M., Glynn, N. W., Zhang, Y., Saba, S., & Hernandez, I. (2020). Real-world direct comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Medicare beneficiaries with atrial fibrillation. The American Journal of Cardiology, 126, 29-36.

Young, G., Lensing, A. W., Monagle, P., Male, C., Thelen, K., Willmann, S., Palumbo, J. S., Kumar, R., Nurmeev, I., & Hege, K. (2020). Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. Journal of Thrombosis and Haemostasis, 18(7), 1672-1685.

Zeitouni, M., Giczewska, A., Lopes, R. D., Wojdyla, D. M., Christersson, C., Siegbahn, A., De Caterina, R., Steg, P. G., Granger, C. B., & Wallentin, L. (2020). Clinical and pharmacological effects of apixaban dose adjustment in the ARISTOTLE trial. Journal of the American College of Cardiology, 75(10), 1145-1155.